Bloomberg is reporting today that:
“Sanofi and Regeneron Pharmaceuticals Inc. (REGN)’s experimental treatment alirocumab lowered cholesterol three times more than Merck & Co. (MRK)’s Zetia in the first late-stage study of a drug that may garner $3 billion sales annually.”
The full story here:
bloomberg.com/news/2013-10-1 … study.html
(Seems Merck can’t catch a break these days.)